Insider Buying: Quoin Pharmaceuticals (NASDAQ:QNRX) Director Acquires $128,640.48 in Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Director Dennis Langer purchased 15,152 shares of the business’s stock in a transaction dated Tuesday, October 14th. The shares were purchased at an average cost of $8.49 per share, with a total value of $128,640.48. Following the completion of the purchase, the director directly owned 15,153 shares in the company, valued at approximately $128,648.97. This represents a 1,515,200.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Quoin Pharmaceuticals Price Performance

QNRX opened at $14.89 on Friday. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a fifty-two week low of $5.01 and a fifty-two week high of $48.30. The business has a 50-day moving average of $8.45 and a 200-day moving average of $8.05. The company has a market capitalization of $8.76 million, a PE ratio of -0.36 and a beta of 1.66.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($6.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.83) by $0.55. On average, equities research analysts expect that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -2.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Quoin Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.